CVC  NYBC Ventures

https://www.nybcventures.org/





     Office Locations:

420 Boylston St. #501
Boston, MA 02116

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    New York Blood Center created NYBC Ventures to accelerate innovation in blood-related fields and cellular therapies and technology. New York Blood Center established the fund with a $50M investment and a mission to improve patients' lives by advancing therapeutics, enabling platforms and technologies as well as driving collaborations to further NYBC's impact.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Christopher D. Hillyer General Partner
    Jay Mohr General Partner
    Meg Wood Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/22/2024


      AvenCell Therapeutics


      MA


      $112,000,000


      Series B


     

    Portfolio companies include:


      AvenCell Therapeutics
        web link


      Catena Biosciences


      HealthQuest Capital


      KaloCyte


      StealthCo


      STRM Bio


      Thymmune Therapeutics
        web link


     

    Recent News: